◈ Nootpedia
Compact view
Research pass: medium AAS · Oil injectable SKIP-FOR-NOW MEDIUM

Methenolone

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW MEDIUM

AAS at 20 — even "mild" DHT-derivatives suppress HPG axis and risk durable endocrine harm during late puberty/HPG maturation; reputation as "clean" is mostly relative to harsher AAS, not absolute; expensive + heavily counterfeited makes risk/reward worse than oxandrolone if AAS were ever justified.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-AT-

    No cognitive benefit, real HPG risk during axis maturation, expensive + counterfeit-heavy supply, no clinical evidence base for the use case (athletic body comp). Reconsider only post-30 if body composition becomes a top priority and bloodwork supports it.

  • 30-50, executive maintenance
    C

    If AAS becomes part of a TRT-plus protocol, Primo is one of the more defensible "lean adders" given low estrogenic / low cardiac side-effect profile vs trenbolone/testosterone monotherapy. Still expensive. Still counterfeit-heavy. Still requires bloodwork + endocrinologist supervision.

  • 50+, mild cognitive decline
    N

    relevant. AAS for cognitive decline is not supported; if hypogonadism is present, testosterone replacement is the indicated treatment, not Primo.

  • Anxiety-prone
    V

    Some users report Primo is easier on mood than 19-nors, but androgenic compounds can still drive irritability/anxiety in susceptible users. Not a recommended choice.

  • High athletic load, tested status
    WADA-

    Detectable in urine for months post-cycle (long ester + fat-stored metabolites). Tested athletes — never. Untested (Dylan): WADA status irrelevant, but the SKIP-AT-20 logic still applies.

  • Sleep-disordered
    AAS

    class can disrupt sleep architecture. Not the right tool.

  • Recovery-focused (post-injury, post-illness)
    M

    has historical clinical use at low doses for post-surgical/wasting recovery. But for an otherwise healthy 20yo, BPC-157, TB-500, peptides, and basic protein/sleep hygiene cover this without HPG suppression. Not Primo.

  • Strength/anabolic-focused
    S

    gains from Primo are modest. If a strength-focused AAS conversation ever opens (it shouldn't at 20), testosterone enanthate is the more cost-effective and better-evidenced option.

▸ Subjective experience (deep)

Users report:

  • Slow, lean, "quality" gains over 8-12 weeks at moderate doses (300-500 mg/week injectable).
  • Minimal water retention, no bloat.
  • Mood often described as stable or slightly improved (vs harsher 19-nors which can drive mood issues).
  • Strength gains modest compared to testosterone or trenbolone.
  • Libido often preserved or mildly elevated early-cycle (DHT-class compounds), but suppression of endogenous T can collapse libido later in cycle if not paired with exogenous testosterone.
  • Subjective cognitive effect: minimal → mildly positive (not a known nootropic, but androgen-receptor activity in CNS may produce subtle drive/confidence shift).
▸ Tolerance + cycling deep dive
  • Tolerance buildup: AR downregulation occurs with all AAS — not "tolerance" in CNS sense, but receptor saturation/downregulation creates diminishing returns past 12 weeks.
  • Recommended cycle: 8-12 weeks on, then off + PCT for recovery duration roughly equal to cycle length.
  • Reset protocol if needed: PCT (clomid 50/50/25/25 + tamoxifen 20/20/10/10 over 4 weeks is one standard approach), bloodwork at 8-12 weeks post-cycle to confirm HPG recovery before any subsequent cycle.
▸ Stacking deep dive

Synergistic with

  • testosterone-enanthate: Primo is almost always run with a testosterone base in adult cycles — exogenous test prevents the symptomatic crash from suppression of endogenous T while Primo provides the lean-tissue effect. Running Primo solo guarantees mid-cycle hypogonadism symptoms (low libido, fatigue, mood drop). N/A for Dylan — SKIP-AT-20.

Avoid stacking with

  • Other DHT-derivatives (oxandrolone, masteron, winstrol): stacking multiple DHT-class compounds compounds androgenic side effects (hair, skin, prostate) and lipid impact without proportional muscle-building gain.
  • Oral 17α-alkylated AAS together: liver burden stacks supralinearly.

Neutral / safe co-administration

  • N/A — not relevant given SKIP verdict.
▸ Drug interactions deep dive
  • AAS class generally: increases warfarin effect (enhanced anticoagulation), can interact with insulin/oral hypoglycemics (improved insulin sensitivity → hypoglycemia risk in diabetics).
  • Methenolone specifically: not a notable CYP inducer/inhibitor at typical doses; few documented pharmacokinetic interactions.
  • Hepatotoxicity (oral acetate) compounds with other hepatotoxins (acetaminophen, alcohol, other oral 17α-alkylated AAS).
▸ Pharmacogenomics
  • 5α-reductase polymorphisms: irrelevant for methenolone itself (already DHT-derived, not a 5αR substrate).
  • AR CAG repeat length: shorter CAG repeats = stronger androgen receptor signaling per unit ligand — users with shorter repeats may experience more pronounced androgenic side effects (hair loss, prostate, skin) at any given dose.
  • SRD5A2 + AR variants jointly determine androgenic side effect profile across all AAS — relevant if a future AAS conversation re-opens.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market UGL (underground lab) Various ~$120-200 / 10 mL @ 100 mg/mL Low Methenolone is the most counterfeited AAS in the world — many UGL "Primo" vials are actually testosterone enanthate or boldenone, sold at Primo prices. Independent lab testing (Anabolic Lab, Janoshik) routinely flags 30-50% of "Primo" submissions as misidentified.
Pharma-grade (Bayer Primobolan Depot) Black-market diversion $300-500 / 5×1 mL ampule pack Med-High when verified Bayer/Schering ampules are themselves counterfeited at high rates. Holographic verification + lot lookup required.
Rx None for performance use N/A N/A Not approved for any current US indication. Some EU use historically.

Primo cost-per-real-mg often exceeds testosterone by 5-10×, and counterfeit risk inflates the effective cost further. This is structurally a worse risk/reward than oxandrolone (also DHT-class, similar "mild" reputation, more verifiable supply chains) for any case where mild AAS were ever considered.

▸ Biomarkers to track (deep)

Not applicable for Dylan (SKIP-AT-20). If this verdict ever flipped post-30:

  • Baseline (before starting): Total + free testosterone, LH, FSH, estradiol (sensitive assay), SHBG, DHT, PSA, full lipid panel + ApoB, hematocrit, ALT/AST/GGT, fasting glucose + HbA1c, blood pressure, resting heart rate, ECG.
  • During use: Lipids + liver enzymes + hematocrit + blood pressure at week 4 and week 8. Estradiol monthly (low for Primo monotherapy; relevant if testosterone base used).
  • Post-cycle (if cycled): Total + free testosterone, LH, FSH at week 4, 8, and 12 post-cycle to confirm HPG recovery. PSA + lipids return to baseline. Failure to recover by week 12 = consult endocrinologist before considering further cycles.
▸ Controversies / open debates Live debate
  • "Primo is mild" — true or marketing? Mild relative to trenbolone, yes. Mild in absolute terms — no. HPG suppression is universal across AAS at supraphysiological doses; reputation as "side-effect-free" is overstated and partly driven by historical celebrity association.
  • Counterfeit prevalence: Some lab-testing initiatives put the "real Primo" rate among UGL submissions below 50%. Means the typical user buying Primo is likely getting cheaper testosterone or boldenone — getting effects (and side effects) of those compounds while paying Primo prices and assuming Primo's milder profile.
  • Brain-development risk at 20: No prospective data on AAS use during late HPG maturation. Mechanism + animal data + case reports of persistent post-AAS hypogonadism in young users justifies precautionary SKIP. Some users argue that "mild" AAS like Primo or Anavar at low doses are categorically different — no evidence supports that distinction at the receptor level.
  • Athletic value vs alternative routes: For a 20yo MMA athlete, the gains from creatine + sleep + protein + structured training already cover most of what Primo would deliver in body composition, without HPG cost. Genuine performance ceiling at 20 is rarely AAS-limited.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-AT-20 (MEDIUM confidence). DHT-derivative AAS, mild but not harmless, real HPG suppression risk during axis maturation. Same family logic as oxandrolone — even "mild" AAS compromise endocrine maturation at 20. Counterfeit supply chain + high cost makes risk/reward worse than alternatives if AAS were ever justified. Reconsider post-30 only if body comp priorities shift and bloodwork supports.
▸ Open questions / gaps Open
  • No prospective clinical data on AAS use specifically in 18-25yo healthy athletes — all SKIP-AT-20 reasoning is mechanistic + extrapolated.
  • Long-term cognitive/mood effects of AAS use in this age range are essentially unstudied — known short-term effects (mood lability, aggression in some users) are documented but long-term CNS sequelae are not.
  • Whether AR CAG repeat length predicts post-cycle HPG recovery in young users — open question, no genetic test currently calibrates this for AAS decisions.
  • Whether DHT-class compounds carry distinct neurosteroid effects from testosterone-class — minimal data.
▸ Sources (full, with our context)
  • Hartgens F, Kuipers H. (2004). "Effects of androgenic-anabolic steroids in athletes." Sports Medicine 34(8): 513-554. — Class overview including methenolone, side effect profiles.
  • Kicman AT. (2008). "Pharmacology of anabolic steroids." British Journal of Pharmacology 154(3): 502-521. — Mechanism review including DHT-derivatives.
  • Rasmussen JJ et al. (2016). "Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation." PLoS One 11(8). — Persistent post-AAS hypogonadism documentation.
  • Anabolic Lab (anabolic.org) — Independent UGL/pharma testing data on Primo counterfeit rates.
  • Llewellyn W. Anabolics (11th ed., 2017). — Reference text on methenolone pharmacology, dosing, sourcing realities. Not a peer-reviewed source but the standard reference for AAS literature in the bodybuilding/sports-medicine gray area.
  • Pope HG Jr et al. (2014). "Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement." Endocrine Reviews 35(3): 341-375. — Comprehensive AAS risk review including age-specific concerns.
Back to compact view